Navigation Links
Review finds conflicts of interest in many cancer studies
Date:5/10/2009

A new analysis finds that a considerable number of clinical cancer studies published in respected medical journals have financial connections to pharmaceutical companies. Published in the June 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that conflicts of interest may cause some researchers to report biased results that are favorable to companies.

Ties between clinical researchers and companies that make medical devices and drugs have become increasingly complex and controversial, particularly as more researchers compete for scarce federal research funds. In addition to using industry money to support their research, some investigators receive consulting fees, own stock and hold positions within companies that profit from selling the very products they are investigating. These conflicts of interest have raised concerns that studies with ties to industry are biased and are not designed to provide a true test of medical therapies. Many medical journals now require researchers to disclose potential conflicts of interest in the articles they submit for publication.

To get sense of the frequency and impact of conflicts of interest in clinical cancer research, Dr. Reshma Jagsi of the University of Michigan and colleagues reviewed cancer studies appearing in eight highly regarded journals in 2006. These journals included the New England Journal of Medicine; JAMA; the Lancet; the Journal of Clinical Oncology; the Journal of the National Cancer Institute; Lancet Oncology; Clinical Cancer Research; and CANCER.

Of the 1,534 cancer studies identified in these journals, 29 percent had conflicts of interest that were apparent from review of published author declarations and authorship lists (including industry funding, consulting fees to authors, co-authorship by industry employees, etc.), and 17 percent declared industry funding. Conflicts of interest were most often found in articles with primary authors from departments in medical oncology (45 percent), those from North America (33 percent), and those with male first and senior authors (37 percent).

According to the authors, randomized clinical trials that assessed patient survival were more likely to report a survival advantage associated with the intervention when a conflict of interest was present. These trials are the foundation by which drugs, technologies, diagnostic tests, etc. get approved for use in the clinic and therefore shape the way oncologists practice medicine.

The findings also show that studies with industry funding were more likely to focus on treatment than studies without industry funding (62 percent vs. 36 percent). They were less likely than studies not declaring industry funding to focus on epidemiology, prevention, risk factors, screening or diagnostic methods (20 percent vs. 47 percent).

This analysis revealed that conflicts of interest exist in a considerable number of clinical cancer research articles published in important journals. The authors noted that "attempts to disentangle the cancer research effort from industry merit further attention, and journals should embrace both rigorous standards of disclosure and heightened scrutiny when conflicts exist."


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
3. Arbios Systems, Incs Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
4. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
5. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
6. Peer-Reviewed, Online Database Showcases Local, County and State Pandemic Planning
7. InstaCare Corp. Reviewing M&A Plans
8. CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path
9. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
10. Multicountry review shows that Bug Buster Kits reduce head lice and social stigma
11. MaxLife Fund Corp. retains the Law firm, Anslow & Jaclin, LLP of Manalapan, N.J., to review MaxLife Fund Corp. options to be listed on the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Innovatum will demonstrate capabilities of ... Healthcare Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development ... improving patient safety. , Microscan , a global technology leader in ...
(Date:9/21/2017)... ... ... FlipBelt, the fitness brand that specializes in problem solving fitness accessories, has ... the launch of their FlipBelt Crops. , The new fitness bottoms feature an integrated ... at the gym, on the trail, or on-the-go. , “We always thought the FlipBelt ...
(Date:9/20/2017)... ... 2017 , ... FirstAlign ( http://www.firstalign.com ), combines strategies and ... (AI) thinking, announced today the launch of its revamped web presence. , ... offers a more comprehensive understanding of the organization’s business and machine learning solutions. ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... company specializing in medical device compliance and commercialization, has just released a ... activities. , FDA is more adamant than ever about medical device, pharmaceutical, ...
(Date:9/20/2017)... ... 2017 , ... Compliancy Group is proud to announce that ... helped another long-time client pass their Department of Health and Human Services (HHS) ... Thanks to the help of the Compliancy Group's Audit Response Program™, not a ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company ... Novartis Pharma AG to distribute NuvoAir,s spirometry technology to physicians ... spirometry platform and Novartis, commitment to address the unmet medical ... ... "We ...
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
Breaking Medicine Technology: